Objective: Patients with peripheral arterial disease (PAD) have increased risk on future cerebro-and cardiovascular events. Our aim was to examine whether carotid artery reactivity (CAR; a novel, simple procedure to examine endothelial function) predicts cardiovascular events in PAD patients. Background: Increased risk for future cardiovascular events in PAD patients is likely related to endothelial dysfunction, highlighting the necessity for simple assessment of endothelial function. Methods: A total of 172 PAD patients (68 AE 10 years, 67% male) underwent the CAR, which involves ultrasound measurement of carotid artery diameter during sympathetic stimulation produced by 90-second hand immersion in 48C ice-water (ie, cold pressor test). CAR-responses were dichotomized into carotid constriction or dilation. We recorded cardiac and cerebrovascular events, mortality, and clinical progression to percutaneous transluminal angioplasty or loss of patency during 12-month follow-up. Results: Eighty-two PAD patients demonstrated carotid constriction and 90 patients demonstrated dilation. PAD patients with carotid constriction showed more cardiovascular events compared to patients with dilation (Kaplan-Meier Log rank; P < 0.05). Cox proportional hazard models showed that patients with carotid constriction continued to show higher risk for cardiovascular events [hazard ratio: 4.1; 95% confidence interval (CI), 1.3-12.5] and clinical progression (hazard ratio: 2.0; 95% CI, 1.2-3.3), even after adjustment for other risk factors. Ankle brachial pressure index and carotid intima-medial thickness alone did not predict (cardiovascular) event or improve risk assessment beyond that provided by CAR. Conclusion: Carotid vasoconstriction identifies PAD patients with a 4-fold increased risk for future cardiovascular events and 2-fold increased risk for clinical deterioration. CAR provides a simple, novel strategy to predict cardiovascular events and progression in PAD patients. Clinical Trial Registration: www.trialregister.nl/trialreg/index.asp, NTR-4117.
P eripheral arterial disease (PAD) is the result of atherosclerotic arterial stenosis and occlusions in the larger vessels supplying the lower extremities. 1 Patients with PAD have a markedly increased risk for future cardiovascular mortality and morbidity. [1] [2] [3] [4] Endothelial dysfunction contributes to the development and progression of PAD. 5, 6 Endothelial function, often examined as the brachial artery reactivity response to ischemia, in PAD patients is impaired [7] [8] [9] and relates to future cardiovascular events. 10, 11 The recent AHA/ACCguideline on the management of PAD highlighted the need for an easy, simple, and rapid test of endothelial function to predict future adverse events in PAD. 12 Although brachial artery reactivity shows predictive capacity for future cardiovascular events, 10, 11 concerns have been raised regarding practical limitations that prevents the clinical application of this technique.
Carotid artery reactivity (CAR) testing is a simple, noninvasive procedure to examine endothelial function. It involves measuring the carotid artery diameter responses to the sympathetic stimulation produced by the cold pressor test (CPT). 13, 14 The carotid arteries, like coronary arteries, 13, 14 dilate in response to the CPT in healthy subjects, whereas this dilation is attenuated, or reversed to vasoconstriction, in patients with cardiovascular disease. [13] [14] [15] [16] Interestingly, the coronary arteries' response to CPT is a strong, independent predictor of cardiovascular events, 17, 18 but it is not clear whether the carotid response to CPT (ie, CAR) also predicts future cardiovascular events. This study is to our knowledge the first to examine the prognostic value of the CAR in patients with PAD. We hypothesized that CAR-induced vasoconstriction would predict future cardiovascular events in patients with PAD, independent of subject characteristics and clinical status.
METHODS

Participants and Study Approval
We recruited 172 patients with PAD scheduled for a routine visit at the vascular laboratory (Department of Surgery, Radboud University Medical Center, Netherlands) for the study (Fig. 1) . We included PAD patients with present or previous Fontaine classification 2B-3-4, age !18 years, and the ability to provide informed consent. We excluded patients with Raynaud's phenomenon, chronic pain syndrome, open wounds on the upper extremities, arterial-venous shunts, scleroderma, coronary, central and/or PAD interventions within the previous <1 week, and unstable angina pectoris, myocardial infarction, stroke, or heart failure within the previous 3 months. Patients provided written informed consent before participation. The study was approved by the local Ethics Committee (NL-46109.091.13) in accordance with the latest revision of the Declaration of Helsinki. This study was registered as NTR-4117 (Netherlands Trial Registration).
Experimental Design
Patients abstained from strenuous exercise for 24 hours, fasted for !6 hours, and abstained from caffeine and vitamin C, which are known to alter endothelial function, for !18 hours before testing in accordance with guidelines on assessing endothelial function. 20 From the weight (in kilograms), and waist-hip ratio (WHR) were measured by a research nurse. The same vascular surgeon assigned the patient's Fontaine clinical classification. Patients with Fontaine stage !2 performed walking tests to distinguish between Fontaine stages. Finally, the ankle-brachial pressure index (ABPI) was measured based on clinical requirements following recent guidelines. 21 The highest systolic pressure in the right and left posterior tibial or dorsal pedis artery and in the right brachial artery was measured twice, and the average of those 2 measurements was used to calculate the ABPI for each leg. The lowest ABPI of 2 legs was used for analysis. For the purpose of analysis, we compared those above versus below the median ABPI.
CAR
Patients rested on a comfortable bed in a temperature controlled room for at least 5 minutes. Participants were in the supine position with the neck extended for assessment of the carotid artery. Left carotid artery diameter was recorded continuously for 30 seconds before and for 90 seconds during immersion of the hand up to the wrist in ice slush (48C). Images were obtained using a L9-3 MHz linear array probe attached to a high-resolution ultrasound machine. When an optimal image was found, the probe was held stable and the ultrasound parameters were set to optimize the longitudinal, B-mode image of the lumen-arterial wall interface. Following a 30-second baseline assessment of carotid artery diameter, the hand was immersed for 90 seconds with simultaneous and continuous assessment of carotid artery diameter (Fig. 2) .
CAR% responses were assessed for diameter. Analysis of the carotid artery diameter was performed by a single-blinded investigator using custom-designed edge-detection and wall-tracking software, which is largely independent of investigator bias. 22 Details of this technique can be found elsewhere. 23 Baseline diameter was calculated as the mean of data acquired across the 30 seconds preceding the CPT test. After submersion of the hand in ice slush, data were calculated as the mean value for 10-second intervals, involving 8 to 10 full cardiac cycles. Based on these data, we calculated the peak diameter change (ie, the 10-second bin with the highest value, CAR%). The peak diameter change can refer to a maximum constriction or dilation. The direction of this change was determined by a positive (ie, dilation) or negative (ie, constriction) area under the curve.
Reproducibility (coefficient of variation, CV) of diameter responses to CPT was previously assessed with 1-and 24-hour intervals in 50 subjects. Within-day CVs for baseline and peak diameters were 2.2% and 2.6%, whereas day-to-day CVs were 2.3% and 2.7%. Furthermore, the CAR% (ie, maximum change in diameter) showed a within-day reproducibility of 2.6% and betweenday reproducibility of 2.8%. 14 
Intima-media Thickness
Carotid artery intima-media thickness (cIMT), a marker for vascular structure, is related to future development of PAD. 24 To examine whether the CAR relates to future cardiovascular events, independent of the cIMT, we examined cIMT from the same section of the artery as the CAR. We obtained continuous recordings of the cIMT for 10 seconds. Analyses were performed by a blinded researcher, using observer-independent edge-detection and walltracking software. 25 For the purpose of analysis, we compared those above versus below the median cIMT.
Follow-up and Assessment of Adverse Events
After 12 months of follow-up, adverse events were extracted from medical records and verified by a blinded vascular surgeon (M.W.). The Dutch National Death Registration was used to determine mortality. Death certificates of patients who experienced a fatal event were obtained when available to categorize death into CV or non-CV-related mortality. Adverse events were categorized into: cardio-and cerebrovascular events (''cardiovascular events''; cardiovascular event-related mortality, myocardial infarction, coronary revascularisation procedures, transcranial ischemic attack, cerebrovascular accident, carotid surgery, major-and minor amputations, and ischemic bowel disease); ''clinical progression'' that is related to PAD [loss of patency (ie, the presence of restenosis in a previous endovascular reconstructed vessel], endovascular reconstructive surgery using percutaneous transluminal angioplasty, and worsening in Fontaine-classification), and ''all-cause mortality.'' We also grouped these 3 categories to capture all adverse events (''adverse events''). Only the first event was included in the analyses for patients who experienced >1 event. All indications for PTA and revascularisation surgery were discussed before in a multidisciplinary team of vascular surgeons and interventional radiologists, whereas preference of patient and interventional were taken into consideration. All involved members of the multidisciplinary team were blinded to the outcome of the CAR test.
Statistical Analysis
Before our study, we aimed to include 200 PAD patients. This group size is in line with previous studies examining the prognostic value of measures of vascular health, 10, 19 whereas this group size also accounts for potential drop out (10%-15%) and access to sufficient PAD patients (n ¼ 400/annum, 50% inclusion rate). Data are presented as mean AE standard deviation or n (%) unless stated otherwise. Statistical analysis was performed using IBM SPSS Statistics 21.0 (IBM SPSS, IBM Corp, Armonk, NY). Baseline characteristics were assessed for normality with the Shapiro-Wilk test. We adopted unpaired Student t tests (Mann-Whitney U test for non-normally distributed parameters) to compare subject characteristics, comorbidities, clinical status, and medication use between PAD patients with carotid constriction versus dilation. We used logistic regression to assess whether subject characteristics, comorbidities, clinical status, or medication could predict presence of carotid constriction. Analyses to examine whether presence of carotid constriction could predict future events, analyses were performed separately for ''cardiovascular events,'' ''clinical progression,'' ''all-cause mortality,'' and ''adverse events.'' Cumulative event rates of carotid constriction and dilation were estimated with Kaplan-Meier survival analyses, and were calculated with the log-rank test. Cox proportional hazard models were used to calculate hazard ratios, including correction for confounding variables [age, sex, body mass index (BMI), and WHR). These variables were selected based on previous evidence of an association with measures of endothelial function. 14, 20 Analyses were repeated in subgroups in whom we examined cIMT (n ¼ 169) or ABPI (n ¼ 142). We examined whether these clinical measures were related to increased risk for future events, 26 and whether they altered the analyses related to carotid measurement.
RESULTS
Subject characteristics, comorbidities, clinical status, and adequate imaging were obtained in all 172 PAD patients. Median change in carotid artery diameter was 0.8% [95% confidence interval (CI), 19.3%-11.6%). Carotid constriction occurred in 82 patients, whereas vasodilation occurred in 90 patients. Seventy patients (41%) experienced !1 event, which included loss of patency (n ¼ 18), increase in Fontaine-classification (n ¼ 15), percutaneous transluminal angioplasty (n ¼ 44), transient ischemic attack (n ¼ 1), myocardial infarction (n ¼ 4), cerebrovascular accident (n ¼ 3), coronary revascularisation procedures (n ¼ 1), major (n ¼ 7) and minor (n ¼ 1) amputation, and ischemic bowel disease (n ¼ 1). Ten PAD patients died from CV-related mortality (n ¼ 4), cancer-related mortality (n ¼ 2), and unknown cause (n ¼ 4). We found no baseline differences between PAD patients with carotid constriction versus dilation in subject characteristics or comorbidities. Patients with carotid constriction reported lower antiplatelet drugs usage (Table 1) . Logistic regression revealed that none of the subject characteristics, comorbidities, clinical status, or medication use could predict whether a PAD patient would demonstrate carotid constriction (backward likelihood ratio analysis, all parameters, P > 0.05). When comparing patients with and without an adverse event, those with events showed higher prevalence of hypercholesterolemia. Other factors did not differ between groups (Supplemental data 1, http:// links.lww.com/SLA/B330).
Prognostic Value of Carotid Constriction for Future Adverse Events
Kaplan-Meier survival curves demonstrated that PAD patients with carotid constriction report a higher incidence of CV events (P ¼ 0.007), clinical progression (P ¼ 0.005), and adverse events (P ¼ 0.006) compared to carotid dilation (Fig. 3 ). There were no significant differences between groups for all-cause mortality (Log-rank, P ¼ 0.417, Fig. 3 ).
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Event Prediction With Carotid Reactivity Table 2 ).
Added Value of Clinical Measures
In 30 subjects, we were unable to perform a valid ABPI because of noncompressible arteries or amputation. We were unable to perform analysis of cIMT in 3 participants because of technical problems. Analyses for cIMT (n ¼ 169) and ABPI (n ¼ 142) showed no significant effect using the Kaplan-Meier survival analysis for adverse events (Fig. 4) , CV events (Log-rank, P ¼ 0.674 and 0.457, respectively), clinical progression (Log-rank P ¼ 0.484 and 0.153, respectively) or all-cause mortality (Log-rank P ¼ 0.198 and 0.795, respectively).
The Cox proportional hazard models for the carotid constriction (including models 1 and 2) were repeated for the subgroups with data on cIMT and ABPI. Adding cIMT or ABPI to the fully adjusted model did not alter the HR of carotid constriction for future CV events, clinical progression, all-cause mortality, or adverse events (Supplemental material 2, http://links.lww.com/SLA/B330).
DISCUSSION
This is the first study, to our knowledge, to examine the relation between the carotid response to the cold pressor test and future CV events in PAD patients. We found that patients who demonstrated carotid constriction during the cold pressor test had a 4.1-, 2.0-, and 1.8-times increased risk at 1 year of developing a CV event, clinical deterioration and other adverse events, respectively, compared to those with carotid dilation. Importantly, the ability of the carotid vasomotor response to predict CVevents was independent of subject characteristics and more predictive than other common clinical measures such as ABPI and cIMT. This suggests that a measure of (generalized) vascular health is more important than the extent of the (localized) atherosclerotic lesion in PAD patients. Therefore, a simple and noninvasive measure of carotid artery endothelial function can identify PAD patients at increased risk for future adverse CV events and clinical progression.
Dilation Versus Constriction
We 14,27 and others 13, 15, 16 have demonstrated that the CPT produces a gradual dilator or constrictor response. Similarly, normal coronary arteries show an endothelium-mediated dilation that is mediated by the CPT-induced catecholamine-release, which exceeds the direct constrictor effects of catecholamines on smooth muscle cells. 15, 16 However, endothelial dysfunction and/or (partial) endothelial damage impedes endothelium-mediated dilation leading to Data are presented as the hazard ratio and the 95% CI), with stepwise inclusion of a subject characteristics up to model 2.
vasoconstriction. 15 Similar responses in the carotid artery probably explain the distinct dilator or constrictor responses we observed in our study. Surprisingly, other subject characteristics, comorbidities, and clinical measures did not differ between PAD patients demonstrating constriction or dilator responses. This suggests that CV risk factors do not contribute to the distinct vasomotion responses between PAD patients, and that the PAD disease state, rather than subject characteristics or CV risk factors, contributes to carotid artery endothelial dysfunction.
Relation Between the Carotid Vascular Response and Subsequent Events
Current cardiovascular risk factors do not predict future cardiovascular events in patients with PAD. 12 This highlights the potential utility of the carotid artery vasomotor response in predicting future cardiovascular events. Others have demonstrated that brachial artery flow-mediated dilation predicts future cardiovascular events in PAD patients, 10, 11 but this technique is more difficult than our approach of simply measuring the relatively large carotid diameter (ie, $7.5 mm) in response to the CPT. Previous studies have also not measured clinical progression, whereas we found that carotid constriction had a 2-fold increased risk for loss of patency, endovascular reconstructive surgery, and/or worsening in Fontaine-classification. This knowledge may allow clinicians to treat more aggressively in those patients at risk for clinical deterioration.
Others have found that the coronary artery response to CPT predicts future cardiovascular events. 17, 18 Results from the present study suggest that the carotid artery response to the CPT is a surrogate for coronary arteries. This is supported by our previous within-subject observation that a subject's carotid and coronary response to the CPT are similar. 14, 27 This observation also supports the concept that atherosclerosis is a whole body, generalized disease of the endothelium, such that an abnormal response in 1 vascular bed is likely also present other vascular beds. Consistent with this concept is the observation that abnormal brachial artery dilator responses to endothelial stimulation using increased flow 6 or acetylcholine 28 are associated with abnormal coronary artery responses to endothelial stimulation.
ABPI is useful in both the diagnosis of PAD 29 and predicting the need for revascularisation. 2, 30, 31 Examining cIMT has also been useful in predicting atherosclerotic risk in some, but not all, studies of the general population. 24, 32 We found no relation between either ABPI or cIMT and future CV events, clinical progression or adverse events. Furthermore, adding these clinical measures to the statistical model did not alter the relationship between CAR and future (CV) events. The finding that ABPI and cIMT are not related to future events contrasts with previous work performed in the general population, 2, 30, 31 but is largely in agreement with studies performed in PAD. 12, 33 Abnormal ABPI and cIMT indicate the presence of atherosclerosis, whereas coronary responses to CPT reflect endothelial function. This suggests that in individuals with known CVD, the impact of the atherosclerotic process on the endothelium is more important than the atherosclerotic lesion in predicting CV events.
A potential limitation of our study is that we did not include other biomarkers, such as high-sensitive C-reactive protein, which are demonstrated to have potential prognostic value in PAD for future CV events. 37, 38 Unfortunately, we did not assess these biomarkers to examine the potential added value of combining these markers with the CAR, which may be relevant as these biomarkers may provide additional information to our in vivo measure of endothelial function.
Clinical Relevance
The CAR to CPT procedure is easy to perform, low-cost, noninvasive, and requires minimal time and equipment. The simplicity of the test is supported by an excellent reproducibility. 14 Moreover, in contrast to the majority of subject and/or disease characteristics, the carotid artery vasomotor response to CPT identified subjects with an increased risk for future events. The clinical relevance of the CAR may relate the identification of PAD patients who are more vulnerable to nonadherence and/or complications during surgery. For example, although symptomatic PAD should all be on drug therapy, compliance to therapy is relatively poor. [34] [35] [36] The CAR-test may help to identify individuals in whom it is of special importance to maintain compliance to drug therapy. Additionally, CV comorbidity in PAD patients is associated with increased perioperative CV risk. Future studies are needed to assess the potential added value of the CAR to estimate perioperative risk in PAD patients.
In conclusion, our study provides the first evidence that CAR, independent of subject characteristics and clinical measures such as cIMT and ABPI, predicts future adverse (CV) events and clinical progression in PAD patients. The presence of carotid artery constriction during the CPT is associated with a 4-fold increased risk for future CV events and 2-fold increased risk for clinical progression. These observations suggest that the CAR should be further evaluated for its ability to predict future risk in patients with PAD.
